Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Abstract

Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme; CLEAR ClinicalTrials.gov number, NCT02811861.).

Keywords

LenvatinibPembrolizumabEverolimusSunitinibRenal cell carcinomaMedicineOncologyInternal medicineImmunotherapyCancer

MeSH Terms

AdultAgedAged80 and overAntibodiesMonoclonalHumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarcinomaRenal CellEverolimusFemaleHumansKidney NeoplasmsMaleMiddle AgedPhenylurea CompoundsProgrammed Cell Death 1 ReceptorProgression-Free SurvivalProtein Kinase InhibitorsQuinolinesSunitinibSurvival Analysis

Affiliated Institutions

Related Publications

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert , Jacob Schachter , Georgina V. Long +19 more

The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...

2015 New England Journal of Medicine 5661 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer , Nizar M. Tannir , Ray McDermott +29 more

Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previo...

2018 New England Journal of Medicine 4403 citations

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

Publication Info

Year: 2021
Type: article
Volume: 384
Issue: 14
Pages: 1289-1300
Citations: 1597
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1597

OpenAlex

Influential

1398

CrossRef

Cite This

APA Style

                            
                                
                                    Robert J. Motzer, 
                                
                                    B. Yа. Alekseev, 
                                
                                    Sun Young Rha
                                
                                et al.
                            
                            (2021). 
                            Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. 
                            New England Journal of Medicine
                            , 384
                            (14)
                            , 1289-1300.
                            https://doi.org/10.1056/nejmoa2035716
                        

Identifiers

DOI: 10.1056/nejmoa2035716
PMID: 33616314

Data Quality

Data completeness: 90%